ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
Dow Jones
39.512,84
0,32%
Euro vs US Dollar
1,07885
0,00%
Bitcoin
61.177,36
0,63%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Olema Pharmaceuticals Inc (OLMA)

  7. Olema Pharmaceuticals Inc (OLMA) News

OLMA

Olema Pharmaceuticals (OLMA)

Olema Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:OLMA
DatumZeitQuelleÜberschriftSymbolFirma
08/05/202422h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OLMAOlema Pharmaceuticals Inc
08/05/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OLMAOlema Pharmaceuticals Inc
08/05/202422h02GlobeNewswire Inc.Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
08/05/202413h02GlobeNewswire Inc.Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual CongressNASDAQ:OLMAOlema Pharmaceuticals Inc
07/05/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
06/05/202422h00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
02/05/202422h37GlobeNewswire Inc.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OLMAOlema Pharmaceuticals Inc
01/05/202413h02GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor Conferences in MayNASDAQ:OLMAOlema Pharmaceuticals Inc
08/04/202422h30GlobeNewswire Inc.Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual ConferenceNASDAQ:OLMAOlema Pharmaceuticals Inc
02/04/202422h29GlobeNewswire Inc.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OLMAOlema Pharmaceuticals Inc
11/03/202421h31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OLMAOlema Pharmaceuticals Inc
11/03/202421h15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OLMAOlema Pharmaceuticals Inc
11/03/202421h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OLMAOlema Pharmaceuticals Inc
11/03/202421h03GlobeNewswire Inc.Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
06/03/202413h03GlobeNewswire Inc.Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 InhibitorsNASDAQ:OLMAOlema Pharmaceuticals Inc
04/03/202423h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
04/03/202422h30GlobeNewswire Inc.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OLMAOlema Pharmaceuticals Inc
29/02/202420h26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
14/02/202422h08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
14/02/202418h53Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
12/02/202423h16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OLMAOlema Pharmaceuticals Inc
12/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OLMAOlema Pharmaceuticals Inc
06/02/202413h01GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor ConferencesNASDAQ:OLMAOlema Pharmaceuticals Inc
05/02/202423h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
05/02/202423h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
05/02/202423h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
02/02/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
02/02/202422h30GlobeNewswire Inc.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OLMAOlema Pharmaceuticals Inc
01/02/202421h24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
31/01/202422h21Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OLMAOlema Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:OLMA

Kürzlich von Ihnen besucht

NASDAQ
AAPL
Apple
NASDAQ
NVDA
NVIDIA
DBI
MDAX
MDAX
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
MRK
Merck
FX
EURJPY
Euro vs Yen
AMEX
SPY
SPDR S&P 500
NASDAQ
AMZN
Amazon.com
TG
D7G
Nel ASA
NYSE
MCD
McDonalds
DBI
TDXP
Tec DAX
FX
EURGBP
Euro vs Sterling
TG
CBK
Commerzbank
COIN
SOLUSD
Solana
USOTC
BNPQY
BNP Paribas (QX)
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten